VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX - Get Free Report) in a research note issued to investors on Monday. The firm set a "sell" rating on the stock.

Separately, Benchmark reaffirmed a "hold" rating on shares of VolitionRx in a research note on Friday, August 16th.

VolitionRx Price Performance

VolitionRx stock traded down $0.00 during midday trading on Monday, hitting $0.60. The company's stock had a trading volume of 36,693 shares, compared to its average volume of 161,068. The company has a 50-day moving average price of $0.68 and a two-hundred day moving average price of $0.69. VolitionRx has a 1-year low of $0.43 and a 1-year high of $1.23. The company has a market cap of $55.26 million, a price-to-earnings ratio of -1.50 and a beta of 1.10.

VolitionRx (NYSE:VNRX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01. The company had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.34 million. Sell-side analysts forecast that VolitionRx will post -0.31 EPS for the current year.

Insider Buying and Selling at VolitionRx

In other VolitionRx news, Director Guy Archibald Innes purchased 150,000 shares of the stock in a transaction dated Tuesday, August 20th. The stock was bought at an average price of $0.67 per share, with a total value of $100,500.00. Following the acquisition, the director now owns 406,683 shares of the company's stock, valued at approximately $272,477.61. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 12.80% of the company's stock.

Institutional Trading of VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC grew its position in VolitionRx Limited (NYSE:VNRX - Free Report) by 78.8% in the third quarter, according to its most recent filing with the SEC. The fund owned 45,959 shares of the company's stock after acquiring an additional 20,249 shares during the period. Ground Swell Capital LLC's holdings in VolitionRx were worth $28,000 as of its most recent filing with the SEC. 8.09% of the stock is owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.